AB Science Reduces Operational Deficit but Sees Net Loss Increase
AB Science has released its financial results for the first half of 2025, revealing a 24% reduction in its operational deficit, but a 15.8% increase in its net loss compared to the previous year.
Operational and Financial Performance
AB Science recorded a decrease in its operational deficit, from 3.582 million euros in the first half of 2024 to 2.728 million euros as of June 30, 2025, marking a 23.8% reduction. However, despite this operational improvement, the net loss increased to 5.177 million euros from 4.469 million euros the previous year, an increase of 15.8%. The company's revenue decreased to 515,000 euros as of June 30, 2025, down from 560,000 euros on June 30, 2024. This decline is attributed to a temporary decrease in sales of Masivet at the 50 mg dosage. Administrative expenses decreased by 31.1%, while research and development expenses were reduced by 21.7%.
Advancements in Clinical Research
AB Science continued to make progress in clinical research. Authorizations were obtained for phase 3 confirmatory studies on masitinib for amyotrophic lateral sclerosis (ALS) and hormone-resistant metastatic prostate cancer, from authorities such as the EMA and the FDA. Additionally, new data were published demonstrating the efficacy of masitinib in Alzheimer's disease. Concurrently, the company was granted a US patent covering the use of masitinib in the treatment of sickle cell disease until 2040. Regarding the microtubules platform, an orphan drug designation for the molecule AB8939 was obtained from the EMA for the treatment of acute myeloid leukemia.
Financial Developments
Financially, AB Science raised a total capital of 6.3 million euros through private placements during the first half of 2025, primarily to support the clinical development of the AB8939 program. The company also reached a principle agreement to defer the repayment of certain state-guaranteed loans by two years, but the implementation of this agreement depends on a deferral of the repayment of a loan taken out with the EIB. In 2025, AB Science received a partial payment of the 2023 Research Tax Credit (CIR), amounting to 2.934 million euros.
